Clinical Trial Update: A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating pharmacokinetics, pharmacodynamics, and safety of anifrolumab in adults with active cutaneous/systemic lupus erythematosus has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Anifrolumab (anifrolumab)

Snippet

Sponsor: AstraZeneca | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: COMPLETED | Results posted: 2019-12-18